Actively Recruiting
Evaluating Brain-AVOidant Proton Craniospinal Irradiation for Adults with Leptomeningeal Metastases from Solid Tumors
Led by University of Miami · Updated on 2026-10-23
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of Brain-AVOidant proton craniospinal irradiation BRAVO pCSI for adults with leptomeningeal metastases from solid tumors. This trial aims to study how well this targeted radiation treatment controls cancer spread in the central nervous system and improves patient outcomes in this condition. Participants in the treatment group receive BRAVO pCSI, which delivers a total radiation dose of 30 Gy Cobalt Gray Equivalent in 10 sessions over about two weeks. Those who choose not to undergo this radiation can join a non-interventional group that undergoes the same assessments but receives no study treatment. Treatment must start within 21 days of enrollment. Throughout the study, participants undergo regular imaging scans, cerebrospinal fluid and blood tests, neurocognitive evaluations, and quality-of-life assessments. Researchers will measure central nervous system progression-free survival for up to 1.5 years, along with additional outcomes like overall survival, treatment response, safety, cognitive function, depression, fatigue, and symptom severity. The study involves ongoing monitoring to assess the impact of the treatment over time.
CONDITIONS
Brief Title
BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies
Research Team
M
Morgan Freret, MD
M
Markus Bredel, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here